All articles tagged with #semaglutide
A new study indicates semaglutide may repair osteoarthritis damage by reprogramming cartilage-cell energy metabolism via the GLP-1R–AMPK–PFKFB3 axis, with mouse data showing protection beyond weight loss and a small human trial (HA + semaglutide) reporting reduced pain and thicker cartilage—suggesting a weight-loss–independent mechanism that requires further clinical validation.
A Rhode Island nonprofit’s Open Doors pilot is giving free weekly GLP-1 injections (semaglutide–based) to women in addiction recovery, with participants reporting reduced cravings, steadier thinking, and improved life stability. While some studies hint GLP-1s dampen the rewarding effects of drugs and alcohol, the medications are not FDA-approved for addiction and funding for the pilot runs for 18 months, raising questions about long-term access. Experts urge cautious optimism, noting risks if treatment is stopped and that this is not a universal cure.
Novo Nordisk filed a lawsuit seeking a permanent ban and damages against Hims & Hers for allegedly selling compounded, patent-infringing versions of Wegovy (semaglutide); Hims paused its obesity-pill copycat after regulatory scrutiny as FDA actions loom, underscoring a broader crackdown on compounded GLP-1 drugs used by as many as 1.5 million Americans amid intense obesity-drug competition.
As Novo Nordisk’s semaglutide patent nears expiry in March, Indian pharma companies are ramping up generic production of semaglutide injections (and competitors like tirzepatide), with price expectations falling from hundreds of dollars per month to about $77 initially and potentially around $40 over time. Analysts say this could trigger a global price war and transform India into a major low-cost supplier for obesity and diabetes treatments, though experts warn against misuse and stress the need for lifestyle interventions alongside medication.
Novo Nordisk says Hims & Hers’ new $49/month, compounded semaglutide version of Wegovy is illegal mass compounding and unsafe, pledging legal action; the FDA has warned against copycat GLP‑1 drugs. The move intensifies price competition in obesity drugs, with Novo forecasting up to a 13% drop in net sales and shares for Novo Nordisk and Lilly slipping.
An up-to-date primer on GLP-1 therapies through 2026, detailing approved drugs (Ozempic, Wegovy, Rybelsus, Mounjaro/Zepbound, Victoza/Saxenda, Trulicity, Byetta/Bydureon, Adlyxin/Lyxumia) and promising ones (orforglipron, retatrutide), their dosing (daily vs weekly), diabetes vs obesity uses, and safety notes (thyroid tumor risk), plus the state of generics and the 2026 pipeline.
A Pew Research Center analysis of 2024–2025 data finds about 40% of U.S. adults are obese (around 10% severely obese) with a slight decline since 2017–18; 65% say willpower alone isn’t enough to lose weight. Roughly half of Americans report hearing about Ozempic, Wegovy, and similar GLP-1 drugs extremely or very often, with women and older adults more likely to say so. Public opinion skews toward using GLP-1s for obesity-related health conditions rather than for weight loss alone. GLP-1 drugs have generated billions in revenue—Novo Nordisk’s 2024 GLP-1 sales totaled about $31.1 billion (majority from the U.S.), and Lilly’s Mounjaro/Zepbound have also surged. Medicaid coverage varies by state (13 cover GLP-1s for obesity, 7 cover some weight-loss drugs but not GLP-1s), and prescriptions rose from about 1.3 million in 2019 to 8.4 million in 2024, with spending climbing to roughly $8.6 billion.
The FDA has approved Wegovy as an oral pill for adults, delivering the same active ingredient (semaglutide) as the weekly injection. Because the pill must pass through the digestive system, it’s taken once daily on an empty stomach with a full glass of water and a 30‑minute wait before eating. The pill uses a higher daily dose (25 mg) than the injection (2.4 mg weekly), and trials suggest similar weight‑loss results between forms (about 13.9% with the pill vs 14.4% with the injection). Side effects are primarily gastrointestinal for both forms. The pill is not yet approved for adolescents (12+), can be stored at room temperature, and costs and insurance coverage may influence which form a patient chooses.
A study suggests that semaglutide may protect the heart independently of weight loss, potentially through direct effects on cardiovascular health, with benefits observed across different weight groups and linked partly to reduced waist size, indicating broader uses for the drug beyond weight management.
The FDA has approved a daily pill version of Wegovy, a popular anti-obesity drug by Novo Nordisk, offering an alternative to the weekly injection with similar effectiveness in weight loss, and expected to be available in early January for $149 per month.
The article discusses the potential of Ozempic (semaglutide), a drug primarily used for diabetes and obesity, to treat early-stage Alzheimer's disease, highlighting upcoming clinical trial results that could signal a breakthrough in Alzheimer's treatment.
Research suggests that blockbuster obesity drugs like semaglutide may have potential in treating addiction by acting on brain pathways related to reward and craving, with ongoing clinical trials exploring their efficacy for alcohol, nicotine, and opioid dependence, potentially revolutionizing addiction medicine.
New research shows that semaglutide, used in Ozempic and Wegovy, can protect against heart disease independently of weight loss, suggesting its benefits extend beyond just reducing body weight, potentially influencing future treatment guidelines for cardiovascular health.
A large study finds that the weight-loss drug semaglutide reduces the risk of heart attack and stroke regardless of weight loss amount, with waist size reduction also linked to better heart outcomes, suggesting broader benefits beyond weight loss.
A woman with nausea and abdominal pain was found to have a gastric bezoar, likely caused by semaglutide, a medication that delays gastric emptying. The bezoar was successfully dissolved using diet cola, highlighting an effective, non-invasive treatment for such cases. Discontinuing the medication and using soda alleviated her symptoms, with her condition improving significantly.